The New Year started excellently for MID-Frail with the first patients being enrolled into the study. This happened in Spain where there are two active sites and three patients have been enrolled so far. With this, a crucial study milestone has been achieved. You can download the latest newsletter [1].

A special thank you to Drs Castro and Manzarbeitia, and congratulations to the team at the Hospital de Getafe. MID-Frail is also progressing in other countries, with several sites close to recruiting their first patient. The Czech Republic is leading the way with Investigator and initiation meetings completed at all trial sites. Four sites are now actively recruiting, and six patients have been screened and found eligible; other sites areexpected to start recruitment soon .

Towards the end of last year, Néboa Zozaya and Juan Oliva from the Universidad de Castilla-La Mancha volunteered to write an instructional article for this newsletter on the economic impact of diabetes and the importance of getting an accurate estimate of the size of the costs. One of our major challenges will be to capture a thorough picture of health and social resource expenditure associated with the treatment and care of the study subjects for each of the participant countries. It will only be possible to achieve this if each of the countries involved in the MID-Frail study provides precise, detailed and up-to-date information on resource use, unit costs and treatment pathways. The summary article is published in the newsletter.

The manuscript describing the study protocol submitted to the journal ‘Trials’ has been published [2].

References

1. MID-Frail consortium newsletter #5
2. Rodríguez-Mañas L, et al. An evaluation of the effectiveness of a multi-modal intervention in frail and pre-frail older people with type 2 diabetes--the MID-Frail study: study protocol for a randomised controlled trial. Trials. 2014 Jan 24;15:34.